PCM
BJDX icon

Perkins Capital Management’s Bluejay Diagnostics BJDX Stock Holding History

Perkins Capital Management’s Portfolio BJDX Stock Details BJDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1
Closed -$25K – 106
2022
Q1 		$25K Hold
1
– – 0.02% 107
2021
Q4 		$58K Buy
+1
New +$98.3K 0.04% 103

Other funds holding BJDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Perkins Capital Management's BJDX Position: Q2 2022 in Review

Perkins Capital Management sold out of Bluejay Diagnostics (BJDX) in Q2 2022, closing a stake of 1 share — an estimated $25K sold.

Perkins Capital Management first reported a position in BJDX in Q4 2021 and held it in 2 quarters. The position peaked at $58K in Q4 2021. 6 funds tracked by Wall St. Rank hold BJDX as of Q2 2022.

  • Perkins Capital Management reported no remaining Bluejay Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Perkins Capital Management sold 1 Bluejay Diagnostics share in Q2 2022, an estimated $25K.
  • Perkins Capital Management first reported a position in Bluejay Diagnostics in Q4 2021 and held it in 2 quarters.
  • Perkins Capital Management's Bluejay Diagnostics position peaked at $58K in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q2 2022.

Based on Perkins Capital Management's 13F filing for Q2 2022, filed 29 Jul 2022.